iBet uBet web content aggregator. Adding the entire web to your favor.
Link to original content: http://es.statista.com/outlook/hmo/pharmaceuticals/anti-coagulants/australia
Definition:
The Anti-Coagulants market covers drugs that prevent blood from clotting, i.e., that prolong the clotting time. Anti-coagulants are certain types of antithrombotics, which are often also called blood thinners. Neither thrombolytic drugs, which dissolve clots after they have formed, nor other anti-thrombotics, such as antiplatetelet drugs, are covered in this market.
Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).
Company examples: Bristol Myers Squibb, Bayer, Sanofi, Johnson & Johnson
Notes: Data shown is using current exchange rates and reflects market impacts of the Russia-Ukraine war.
Most recent update: Jun 2024
Source: Statista Market Insights
Notes: The chart “Comparable Estimates” shows the forecasted development of the selected market from different sources. Please see the additional information for methodology and publication date.
Most recent update: Mar 2024
The Anti-Coagulants market in Australia has been steadily growing over the past few years, driven by several factors that have contributed to an increase in demand for these medications.
Customer preferences: One of the main factors driving the growth of the Anti-Coagulants market in Australia is the aging population. As people age, they become more susceptible to a range of health issues, including blood clots, which can lead to serious complications such as stroke or heart attack. As a result, there has been an increased demand for Anti-Coagulants medications among older Australians.
Trends in the market: Another trend that has contributed to the growth of the Anti-Coagulants market in Australia is the increasing prevalence of lifestyle diseases such as obesity and diabetes. These conditions can increase the risk of blood clots, and as a result, more Australians are turning to Anti-Coagulants medications to manage their health.
Local special circumstances: One of the unique aspects of the Anti-Coagulants market in Australia is the country's healthcare system, which is a mix of public and private providers. This has led to a situation where different medications are available through different channels, with some drugs only available to patients who can afford to pay for them out of pocket.
Underlying macroeconomic factors: Overall, the growth of the Anti-Coagulants market in Australia can be attributed to a combination of demographic, lifestyle, and healthcare factors. As the population continues to age and lifestyle diseases become more prevalent, the demand for these medications is likely to continue to increase in the coming years. However, the availability of different medications through different channels could create challenges for patients and healthcare providers alike.
Most recent update: Jun 2024
Source: Statista Market Insights
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Notes: Based on data from IMF, World Bank, UN and Eurostat
Most recent update: Sep 2024
Source: Statista Market Insights
